SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened community interest driven by high short interest and rising borrow rates, fueling speculation about an impending short squeeze ahead of its upcoming earnings report. Investors are actively discussing the stock's potential for a significant breakout, emphasizing institutional acquisitions and the firm's role in the evolving enterprise AI market.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is surging on the back of institutional interest and speculative enthusiasm surrounding its electro-optic polymer technology, which is increasingly viewed as a critical component for high-speed AI infrastructure. The community is buzzing over potential foundry partnerships and the broader validation of the sector, with many investors holding for long-term catalysts while closely monitoring for any official updates on commercialization.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech Inc. is generating significant community buzz due to its status as a low-float play and its history of volatile price swings following corporate actions like reverse splits. Traders are actively debating whether the stock represents a prime short-squeeze opportunity with potential for explosive gains or if it is a classic pump-and-dump scheme prone to rapid reversals and dilution risks.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure as investors react to a lowered full-year bookings forecast, with the company attributing the slowdown to disruptive new age-verification and child safety measures. The community is sharply divided, with bulls viewing the dip as a long-term accumulation opportunity despite the near-term friction, while bears focus on the potential for continued user growth headwinds and regulatory risks.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending as investors react to a transformational 1.5 billion dollar acquisition of the Long Ridge Energy power plant, a strategic move aimed at pivoting the firm from a pure Bitcoin miner to a broader AI and HPC infrastructure provider. While the community is actively debating the company's management track record and the long-term impact of this capital-intensive expansion, the stock remains a focal point for high-beta traders monitoring the potential for a short squeeze alongside broader rotation into crypto-linked equities.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as investors weigh the company's recent earnings beat and strategic capital moves against ongoing concerns regarding high cash burn and dilution risk. Community discussion is heavily focused on the company's long-term potential tied to the R2 platform ramp-up and production milestones, with investors debating whether current price levels present a buying opportunity or a signal of deeper volatility.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors digest news of potential FDA leadership changes, with the community closely tracking rumors of a former company VP being considered for a key regulatory role. The optimism is fueled by strong HOPE-3 Phase 3 clinical data for its lead therapy, leading many to believe that the path to approval is nearing completion despite recent price volatility caused by speculative short-selling.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense volatility and institutional attention as investors debate its role in the AI datacenter 'supercycle' versus concerns over its current valuation and lack of profitability. The community remains sharply divided, with bulls pointing to expanding production capacity and high-speed transceiver demand while shorts anticipate a potential correction due to the stock's rapid appreciation and insider activity.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is currently generating significant investor interest due to strong revenue growth and expectations for its upcoming earnings report. The community is actively discussing the company's AI-driven marketing capabilities, while some express frustration over price volatility and perceived market manipulation.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is seeing a surge in investor optimism driven by positive registrations in key European markets and anticipation around upcoming AI and robotics product updates. The community remains deeply divided, with bulls actively buying calls to fuel a potential squeeze toward key technical levels while bears continue to highlight extreme valuation concerns and ongoing leadership volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Moderate Buy" by Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the company, MarketBeat...

Tenaya Therapeutics (NASDAQ:TNYA)  Shares Down 5%   - Here's What Happened

Tenaya Therapeutics (NASDAQ:TNYA) Shares Down 5% - What's Next...

Tenaya Therapeutics (NASDAQ:TNYA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen cut shares of Tenaya Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Chardan Capital Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)

Chardan Capital reiterated a "buy" rating and set a $8.00 price target on shares of Tenaya Therapeutics in a research report on Thursday...

Tenaya Therapeutics (NASDAQ:TNYA) Issues Earnings Results, Meets Expectations

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) released its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates...

Lifesci Capital Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Strong-Buy

Lifesci Capital raised shares of Tenaya Therapeutics to a "strong-buy" rating in a report on Thursday...

<ul class="summary-bullets"><li>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam.</li><li>Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.</li></ul> Shares of Tenaya Therapeutics, Inc. (TNYA) pulled back after hours after a significant rally during the regular session on Thursday after the company said that it has entered into a research collaboration deal with Alnylam Pharmaceuticals (ALNY) to potentially develop drugs for cardiovascular disease.TNYA shares pulled back 5% in extended hours of trading after closing up 41% in the regular session.<h2 class="st-heading-2">Deal For Heart Drugs</h2>Under the deal, Tenaya Therapeutics will validate up to 15 gene targets and receive as much as $1.13 billion in development and commercial milestone payments from Alnylam if all the targets lead to approved therapies for cardiovascular disease. Tenaya will receive up to $10 million in the form of an upfront payment, the company said.“By combining our modality agnostic target identification and validation capabilities with Alnylam’s leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease,” Tenaya CEO Faraz Ali said.Alnylam will be responsible for all development and commercialization activities of therapeutics associated with the identified gene targets, the companies said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TNYA stock rose from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.A Stocktwits user said that they are awaiting positive data for Tenaya’s TN401 this year with “no curative competition.” TN-401 is a gene therapy for a heart condition called PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).<stembedurl>https://www.stocktwits.com/Raumerica/message/646689743</stembedurl>Another said that the best part about the deal is that Tenaya will just be researching fifteen additional targets for future commercialisation while still owning all of its own drugs.<stembedurl>https://www.stocktwits.com/Raumerica/message/646703938</stembedurl><a href="https://stocktwits.com/symbol/TNYA">TNYA stock</a> has gained 78% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/owlet-stock-is-down-26-percent-after-hours-after-it-reports-q4-2025-earnings/cZdX4n1RI36">Owlet Stock Is Down 26% After Hours – How Did The Company’s Q4 Results Fare?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

TNYA Pulls Back After Hours Following Significant $1.13B Deal-Spurred Rally

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 

Equity

Tenaya shares closed 40% higher in the regular trading session after it entered into a research collaboration deal with Alnylam Pharmaceuticals. 


Tenaya Therapeutics Stock Jumps After New Alnylam Deal

Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone payments.read more...

Tenaya Therapeutics (TNYA) Projected to Post Earnings on Monday

Tenaya Therapeutics (NASDAQ:TNYA) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...

Tenaya Therapeutics (NASDAQ:TNYA) Major Shareholder Group Gp Lp Column III Sells 658,440 Shares

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 658,440 shares of the company's stock in a transaction on Tuesday, February 24th. The stock was...

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. Its programs include TN-201, TN-401, and TN-301. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Newell Olson in 2016 and is headquartered in South San Francisco, CA.

TNYA
Tenaya Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TNYA News

TNYATenaya Therapeutics Inc